Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is renal medullary carcinoma?
Renal medullary carcinoma (RMC) is a rare and very aggressive cancer that begins in the center (the medulla) of the kidney. Its most striking feature is that it occurs almost exclusively in people with a sickle hemoglobinopathy — most often sickle cell trait, the usually-silent carrier state — and it tends to strike young people, including teenagers and young adults, more often male, and is more common in people of African descent. The tumor's cells uniformly lose a gene called SMARCB1, which pathologists use to confirm the diagnosis. RMC frequently causes blood in the urine, flank pain, or weight loss, and unfortunately it has often already spread by the time it is found. Because it grows and spreads so quickly and resists most ordinary treatments, care centers on prompt platinum-based chemotherapy, with surgery and radiation playing supporting roles.
The main types
Doctors group renal medullary carcinoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic RMC (sickle cell trait) | The usual form, occurring in young people with sickle cell trait or disease; defined by loss of the SMARCB1 protein. |
| SMARCB1-deficient renal cell carcinoma, unclassified (RCCU-MP) | A look-alike tumor with the same SMARCB1 loss and aggressive behavior but without a hemoglobinopathy; treated similarly. |
Staging, in plain terms
RMC is staged with the standard kidney-cancer TNM system — tumor size and extent (T), lymph nodes (N), and distant spread (M) — but in practice the cancer's aggressive biology matters more than the number. Most patients already have spread to lymph nodes or distant organs at diagnosis, so treatment is usually planned as if for advanced disease.
| Kidney-cancer TNM (behavior dominates) | What it generally means |
|---|---|
| Localized (uncommon at diagnosis) | Confined to the kidney. Rare for RMC, but when found this early, surgery combined with chemotherapy offers the best chance. |
| Regional node spread | Spread to nearby lymph nodes — a frequent finding. Treated with chemotherapy, often with surgery when feasible. |
| Metastatic | Spread to distant sites such as the lungs, liver, or bones. The most common presentation; systemic chemotherapy is the backbone. |
The standard of care
Renal Medullary Carcinoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Platinum-based chemotherapy (the backbone)
RMC resists most single agents, so intensive platinum-based combination chemotherapy (for example a platinum drug with paclitaxel and gemcitabine) is the main treatment and is usually started promptly given how fast the disease moves.
Surgery (selected cases)
Removing the kidney can be part of treatment when disease is limited or after chemotherapy has shrunk it, but surgery alone is almost never enough because hidden spread is so common.
Radiation for control and symptoms
Radiation is used to control disease that cannot be removed and to relieve symptoms such as pain from bone metastases; it is supportive rather than curative.
Clinical trials and emerging therapy
Because standard options are limited, enrolling in a clinical trial is strongly encouraged. Investigational approaches target the consequences of SMARCB1 loss, and immunotherapy combinations are being studied.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide. In renal medullary carcinoma, chemotherapy carries the main load, but radiation is a valuable supportive tool: focused techniques like SBRT can control an isolated area of spread, and targeted radiation can quickly relieve pain from a bone metastasis, improving quality of life. Modern image guidance keeps the dose on the tumor while sparing nearby organs. Radiation is painless, given over a short course of daily sessions, and leaves no radioactivity in the body.
The main ways radiation is delivered for renal medullary carcinoma:
Palliative external-beam radiation
Targeted radiation relieves pain and controls tumor at sites such as bone or lymph nodes, shaping the dose to the problem area to ease symptoms quickly.
Stereotactic body radiation (SBRT)
Delivers a few high, focused doses to an isolated metastasis or a spot of progressing disease, controlling it without surgery.
Conformal / IGRT photon radiation
Image-guided, intensity-modulated beams treat tumor in or around the kidney while sparing the bowel, spinal cord, and remaining kidney tissue.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Contemporary update on RMC: A 2025 review consolidated current understanding: nearly all cases occur with a sickle hemoglobinopathy and uniform SMARCB1 loss, platinum-based chemotherapy remains first-line, and outcomes — though still poor — are improving with contemporary, expert-led management.[1]
Kidney Cancer (journal) 2025 (Whaley et al.)
Genomic characterization and outcomes: Genomic studies confirmed SMARCB1 loss as the defining event and showed that any platinum-based chemotherapy roughly doubled median survival in metastatic patients (about 10 versus 5 months) compared with non-platinum treatment.[2]
PMC5771412 (PubMed 28558987)
Single-center series of 135 patients: The largest single-center analysis to date clarified presentation, management patterns, and outcomes, reinforcing the need for prompt platinum chemotherapy and a role for surgery and radiation in selected patients.[3]
European Urology Oncology (S2588-9311(24)00175-5)
Common questions
Does sickle cell trait cause this cancer? Renal medullary carcinoma occurs almost only in people with a sickle hemoglobinopathy, usually sickle cell trait — the carrier state most people never notice. Having the trait is a risk factor, but the cancer is still extremely rare among those who carry it. Researchers are studying whether avoiding intense exertion and dehydration may lower the risk.
Why is chemotherapy used before or instead of surgery? RMC spreads early and fast, so by the time it is found it is usually no longer confined to the kidney. Surgery alone rarely controls it. Platinum-based chemotherapy treats the whole body and is the most effective backbone; surgery is added in selected cases, often after chemotherapy.
What can be done given how aggressive it is? Care is best delivered quickly at a center experienced with this rare cancer, using platinum-based chemotherapy with surgery and radiation in supporting roles. Because standard options are limited, clinical trials testing therapies aimed at SMARCB1 loss and immune-based combinations are an important and encouraged option.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.